Home > Research > Publications & Outputs > Comparison of the risk of hospitalisation among...

Research

Links

Text available via DOI:

View graph of relations

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published
  • Katie Harman
  • Sophie Grace Nash
  • Harriet H. Webster
  • Natalie Groves
  • Jo Hardstaff
  • Jessica Bridgen
  • Paula B. Blomquist
  • Russell Hope
  • Efejiro Ashano
  • Richard Myers
  • Sakib Rokadiya
  • Susan Hopkins
  • Colin S. Brown
  • Meera Chand
  • Gavin Dabrera
  • Simon Thelwall
Close
More...
Article numbere13150
<mark>Journal publication date</mark>28/05/2023
<mark>Journal</mark>Influenza and Other Respiratory Viruses
Issue number5
Volume17
Publication StatusPublished
<mark>Original language</mark>English

Abstract

There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.